Theratechnologies Inc., a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant...
Pfizer Inc. announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)...
Interim analysis of data from the Phase III E.mbrace study (clinical trial identifier: NCT04899336), conducted by an independent data monitoring committee,...
WALTHAM, Mass. Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Invitrogen™ EVOS™ S1000 Spatial Imaging Syste...
Roche announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam...
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for AD...
SpringWorks Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that the U.S. Food ...
Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...
Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced a corporate restr...
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment o...
Global biotechnology leader CSL announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one...
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely acti...
© 2025 Biopharma Boardroom. All Rights Reserved.
